Investors Cheer Armata Pharma's Encouraging Data From Lung Infection Candidate

Armata Pharmaceuticals Inc ARMP announced positive topline results from the completed Phase 1b/2a SWARM-P.a. trial evaluating AP-PA02 for chronic pulmonary Pseudomonas aeruginosa infections in cystic fibrosis patients.
Data indicate that AP-PA02 was well-tolerated with a treatment-emergent adverse event (TEAE) profile similar to a placebo.
Only mild, self-limited adverse events possibly related to the study drug were reported in a few subjects.
PK findings confirm that AP-PA02 can be effectively delivered to the lungs through nebulization with minimal systemic exposure.
Single ascending doses (SAD) and multiple ascending doses (MAD) resulted in a proportional increase in exposure as measured in induced sputum.
Additionally, achieved exposures were relatively consistent from subject to subject.
Trends suggest improvement in bacterial load reduction for subjects treated with AP-PA02 at the end of treatment compared to placebo after ten days of dosing.
Importantly, for subjects with the highest average exposure of susceptible phage, there was the durability of approximately two-log reduction from the end of treatment to the end of the study (day 28 post-dose).
PK/PD analysis indicates significant microbiological impacts in the subjects with the highest exposures.
Armata has dosed the first subject in its Tailwind study of nebulized AP-PA02 in patients with non-cystic fibrosis bronchiectasis.
Price Action: ARMP shares are up 27.60% at $3.19 on the last check Monday.